Welcome to Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments to treat hematological malignancies and prostate cancer across multiple modalities.
We are enrolling patients:
With Relapsed or Refractory B-Cell Malignancies for a Phase 1/2 study of ONCT-808, our ROR1-Targeting Autologous Cell Therapy (NCT05588440)
AND
With Relapsed or Refractory Metastatic Castration Resistant Prostate Cancer for a Phase 1/2 study of ONCT-534, our Dual-Action Androgen Receptor Inhibitor (NCT05917470)
